Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Estimating the survival benefits gained from providing national cancer genetic services to women with a family history of breast cancer.

British journal of cancer - 17 May 2004

Griffith G L, Edwards R T, Gray J, Wilkinson C, Turner J, France B, Bennett P

Abstract excerpt

The aim of this paper is to compare a service offering genetic testing and presymptomatic surveillance to women at increased risk of developing breast cancer with its predecessor of no service at all in terms of survival and quality-adjusted survival (QALYs) by means of a Markov cohort chain simulation model. Genetic assessment and presymptomatic care provided between 0.07-1.61 mean additional life years and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Genetic Testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Markov Chains

Share to Mastectomy

Share to Models, Theoretical

Share to Ovariectomy

Share to Quality-Adjusted Life Years

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 15138471
DOI: 10.1038/sj.bjc.6601794
PMCID: PMC2409461

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Estimating the survival benefits gained from providing national cancer genetic services to women with a family history of breast cancer.PMID 15138471Read ↗

Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.Semantic proximity Read ↗

Cancer genetics services: a systematic review of the economic evidence and issues.Semantic proximity Read ↗

Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers.Semantic proximity Read ↗

Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis.Semantic proximity Read ↗

Cost-effectiveness of testing for breast cancer susceptibility genes.Semantic proximity Read ↗

A discrete event simulation to evaluate the cost effectiveness of germline <i>BRCA1</i> and <i>BRCA2</i> testing in UK women with ovarian cancerSemantic proximity Read ↗

Expanding the criteria for BRCA mutation testing in breast cancer survivors.Semantic proximity Read ↗

Preventing future cancers by testing women with ovarian cancer for BRCA mutations.Semantic proximity Read ↗

Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.Semantic proximity Read ↗

Cost-Effectiveness of Population-Based Multigene Testing for Breast and Ovarian Cancer PreventionSemantic proximity Read ↗

Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population.Semantic proximity Read ↗

Steering a course around the genetic iceberg.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.